【摘要】 目的观察培美曲塞联合顺铂一线治疗晚期非小细胞肺癌(NSCLC)的近期疗效及毒副反应。方法 34例晚期肺癌患者采用培美曲塞联合顺铂治疗方案,其中培美曲塞500 mg/m2,顺铂75 mg/m2。结果 34例患者有效率(CR+PR)为38.24%,疾病控制率(CR+PR+SD)为79.4%,主要毒性反髓抑应为骨制,消化道反应,皮疹等。结论培美曲塞联合顺铂一线治疗晚期非小细胞肺癌疗效较好,毒性反应较低,值得临床推广使用。更多还原

【Abstract】 Objective To investigate the clinical effect and safety of pemetrexed joint with cisplatin for the patients with advanced non-small cell lung cancer( NSCLC). Methods 34 patients with NSCLC received a treatment program with pemetrexed and cisplatin,the dose of pemetrexed was 500 mg / m2,and cisplatin was75 mg / m2. Results The efficiency( CR + PR) of 34 patients was 38. 24%,the disease control rate( CR + PR+ SD) was 79. 4%,and the mainly adverse reactions were bone marrow suppression,gastrointestinal reactions,skin rash. Conclusions The pemetrexed joint with cisplatin has a clear efficacy and slight toxicity for NSCLC,worthy of clinical use.更多还原